There were 632 press releases posted in the last 24 hours and 184,388 in the last 365 days.

Global Letairis (ambrisentan; Gilead/GlaxoSmithKline) Markets, 2016-2017 & 2018-2025

/EIN News/ -- Dublin, June 27, 2019 (GLOBE NEWSWIRE) -- The "Letairis" report has been added to ResearchAndMarkets.com's offering.

Letairis (ambrisentan; Gilead/GlaxoSmithKline) is a selective endothelin type A receptor antagonist. Endothelin is a potent vasoconstrictor with mitogenic, hypertrophic, and pro-inflammatory properties. By preventing endothelin from binding to the endothelin receptor, Letairis blocks the receptor-mediated vasoconstriction of vascular smooth muscle cells.

Analyst Outlook

While second-to-market Letairis (ambrisentan; Gilead/GlaxoSmithKline) has not managed to exceed the historical peak sales of fellow endothelin receptor antagonist (ERA) Tracleer (bosentan; Johnson & Johnson), it has remained a market-leading drug. Given that Letairis will imminently face generic competition in the US in October 2018, with other markets shortly following, the drug has limited opportunities for further uptake within the pulmonary hypertension (PH) market.

Nonetheless, Letairis is expected to continue to benefit from the increasing adoption of ERAs in combination with phosphodiesterase 5 (PDE5) inhibitors based on the AMBITION trial. This will counterbalance some generic erosion and aid in maintaining steady sales despite intensifying competition.

Key Topics Covered:

OVERVIEW

  • Drug Overview
  • Product Profiles

LIST OF FIGURES

  • Letairis: Pulmonary hypertension
  • Letairis for pulmonary hypertension - SWOT analysis
  • The authors drug assessment summary of Letairis for pulmonary hypertension
  • Letairis sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016-25

LIST OF TABLES

  • Letairis drug profile
  • Letairis pivotal trial data in pulmonary arterial hypertension
  • Letairis sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016-25

For more information about this report visit https://www.researchandmarkets.com/r/l8lf32

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs 

22157.jpg